Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 13/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 13/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664577 | 0.83 | CYP1A1 (0.57) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL3665257 | 0.83 | CYP1A1 (0.57) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL4189499 | 0.77 | CYP1A1 (0.62) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL4185022 | 0.76 | CYP1A1 (0.68) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL3664956 | 0.76 | CYP1A1 (0.68) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL1225317 | 0.76 | KDM4E (0.49) | ALDH1A1LMNAHPGD | |
| SCHEMBL4584461 | 0.76 | KDM4E (0.51) | CYP1A2MAPTKMT2ALMNAAPP | |
| SCHEMBL4584462 | 0.76 | KDM4E (0.51) | CYP1A2MAPTKMT2ALMNAAPP | |
| SCHEMBL1225315 | 0.76 | KDM4E (0.49) | ALDH1A1LMNAHPGD | |
| SCHEMBL8218411 | 0.76 | CYP1A1 (0.68) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | CYP1A1 339/4885CYP1A2 616/4885CYP1B1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.